Compare RENX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | ALZN |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.9M |
| IPO Year | N/A | 2021 |
| Metric | RENX | ALZN |
|---|---|---|
| Price | $1.70 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 278.3K | 44.6K |
| Earning Date | 05-22-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.84 |
| 52 Week High | $3.48 | $4.30 |
| Indicator | RENX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 53.46 |
| Support Level | $1.40 | $1.03 |
| Resistance Level | $2.21 | $1.25 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 38.27 | 56.90 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.